Adriamycin inhibits the succinoxidase system and the NADH-oxidase system. Both of the intact mitochondrial enzymes and the pentane-extracted preparations are inhibited. The inhibition can be prevented by a molar ratio of coenzyme to adriamycin of 3:1 for coenzyme QIo (ubiquinone) Adriamycin and related anthracyclines are now widely used in clinical medicine for the chemotherapy of cancer (1). Carter and Blum (2) summarized the wide range of clinical antitumor activities and the integration of adriamycin into combined modality protocols. The clinical use of adriamycin is accompanied by serious side-effects, which rigidly restrict its use. Although cardiotoxicity is the most serious side-effect in cancer patients, there is a spectrum of other major side-effects, including hematologic toxicity. The biochemical elucidation of the mechanism (3) of these side-effects, particularly the cardiotoxicity, has become urgent, and particularly if such knowledge could minimize side-effects.
Adriamycin and related anthracyclines are now widely used in clinical medicine for the chemotherapy of cancer (1) . Carter and Blum (2) summarized the wide range of clinical antitumor activities and the integration of adriamycin into combined modality protocols. The clinical use of adriamycin is accompanied by serious side-effects, which rigidly restrict its use. Although cardiotoxicity is the most serious side-effect in cancer patients, there is a spectrum of other major side-effects, including hematologic toxicity. The biochemical elucidation of the mechanism (3) of these side-effects, particularly the cardiotoxicity, has become urgent, and particularly if such knowledge could minimize side-effects.
We have considered that the cardiotoxicity of adriamycin might be due to inhibition of coenzyme Q1o-enzymes. Data have now been obtained on four forms of coenzyme Q (CoQ) that show that the coenzymes prevent this inhibition in vitro.
The biochemical basis of this study of cardiotoxicity is the knowledge that coenzyme Qio (ubiquinone) is an indispensable component of the succinoxidase and the NADH-oxidase systems and other CoQi0-enzymes which are essential to the electron transfer mechanism and oxidative phosphorylation ("bioenergetics") of mitochondria of the human myocardium. Inhibition (toxicity) of enzymes of respiration could be damaging to the heart, and could range from a minor to a major component of the cardiotoxicity of adriamycin.
METHODS
The methods for these assays with adriamycin, the two aglycones, and the four forms of coenzyme Q have been reported (4) . Preparation of beef heart mitochondria (5) and extraction with pentane (6) were described. The determination of the specific activities of succinoxidase and NADH-oxidase, inhi- bition by adriamycin (7), and determination of protein were described (8) . The antimetabolite CoQio-enzyme preparations were detailed (9) . RESULTS
The data ( (11) . Pentane was used for ex- Although CoQio was more effective than CoQ7 on a molar basis in preventing inhibition, a higher molar ratio of CoQ7 to adriamycin was as effective as CoQio. A 3-fold ratio of CoQio to adriamycin prevented inhibition, and a 5-fold ratio of CoQ7 to adriamycin prevented inhibition. H6CoQ4 and CoQ4 were less effective than CoQ7. Possibly, higher ratios of H65C6Q4 and CoQ4 to adriamycin would effectively prevent inhibition.
These differences, in vitro, between CoQio, CoQ7, H6CoQ4, and CoQ4 for prevention of the inhibition may not be applicable in vivo. The lower-molecular-weight CoQs, such as CoQ4, H6CoQ4, and CoQ7, might possibly reach these mitochondrial These results extend the data of Iwamoto et a4. (7) which showed that adriamycin and other quinones inhibited succinoxidase and NADH-oxidase. The potential of CoQ in cancer treatment has been reviewed by Folkers (13) , and data on the relationships between CoQio and adriamycin for mitochondrial enzymes of bioenergetics have been reported (14) . Kishi and Folkers (4) described data on the-prevention by CoQ1o of the inhibition by adriamycin to CoQio-enzymes in mitochondria from beef heart tissue. enzymes better than CoQio (12 of ubiquinone (CoQlo) on the cardiotoxicity of adriamycin in the isolated rabbit heart system. Bertazzoli et al. (16) reported that the cardiotoxicity of adriamycin in rabbits was prevented by ubiquinone (CoQio). Gosalvez et al. (17) found that adriamycin and daunorubicin inhibited mitochondrial respiration and that state 3, but not state 4, was inhibited. Bachmann et al. (18) reported that adriamycin and daunomycin were the most potent of seven anthracycline antibiotics for damage of mitochondrial function, and that the most toxic compounds induced intraventricular block, bradycardia, and heart failure.
Iwamoto et al. (7) and Kishi and Folkers (4) showed that adriamycin was about four times as inhibitory as daunomycin to succinoxidase. The fact that adriamycinone was about three times as inhibitory as adriamycin to succinoxidase may be because adriamycinone is more lipoidal than adriamycin, and CoQio is lipoidal. The additional hydroxyl group of adriamycin may be critical for binding at the receptor for CoQjo, since it may not affect the electron transfer nature of rings B and C.
The antitumor activity of adriamycin might be largely due to intercalation within DNA helices (19) , and possibly to a minor inhibition of CoQ1o-enzymes in tumor tissue (20) . The cardiotoxicity of adriamycin might be largely due to inhibition of CoQio-enzymes that are present at a high level in cardiac tissue and that function in bioenergetics.
